Progress from Alzheimer's tangles to pathological tau points towards more effective therapies now

Journal of Alzheimer's Disease

Volumn 9, Issue SUPPL. 3, 2006, Pages 257-262

  Lee, Virginia M Y ^a   Trojanowski, John Q ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Microtubules; Neurofibrillary tangles; Tau; Taxol

Indexed keywords

AMYLOID BETA PROTEIN; PACLITAXEL; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; DEGENERATIVE DISEASE; DISEASE COURSE; DRUG APPROVAL; DRUG MECHANISM; FOOD AND DRUG ADMINISTRATION; FRONTOTEMPORAL DEMENTIA; MOUSE; NERVE FIBER TRANSPORT; NEUROFIBRILLARY TANGLE; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NEUROPHARMACOLOGY; NONHUMAN; PAIRED HELICAL FILAMENT; PARKINSONISM; PRIORITY JOURNAL; REVIEW; SENILE PLAQUE; TRANSGENIC MOUSE;

EID: 84880185178     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/jad-2006-9s328     Document Type: Review

References (19)

1. G.T. Bramblett, M. Goedert, R. Jakes, S.E. Merrick, J.Q. Trojanowski and V.M.-Y. Lee, Abnormal tau phosphorylation at Ser396 in Alzheimer's disease recapitulates development and contributes to reduced microtubule binding, Neuron 10 (1993), 1089-1099.
2. G.T. Bramblett, J.Q. Trojanowski and V.M.-Y. Lee, Regions with abundant neurofibrillary pathology in human brain exhibit a selective reduction in levels of binding-competent tau and the accumulation of abnormal tau-isoforms (A68 proteins), Lab Invest 66 (1992), 212-222.
3. L.N. Clark, P. Poorkaj, Z. Wszolek, D.H. Geschwind, Z.Z. Nasreddine, B. Miller, D. Li, H. Payami, F. Awert, K. Markopoulou, A. Andreadis, I. D'Souza, V.M.-Y. Lee, L. Reed, J.Q. Trojanowski, V. Zhukareva, T. Bird, G. Schellenberg and K.C. Wilhelmsen, Pathogenic implications of mutations in the tau gene in pallido-ponto-nigral degeneration and related neurogenerative disorders linked to chromosome 17, Proc Natl Acad Sci USA 95 (1998), 13103-13107.
4. H.M. Fillit and L.M. Refolo, eds, Neurofibrillary Tangles as a Target for Developng New Therapeutics for Alzheimer's Disease - Special Issue, J Molec Neurosci 19(Issue 3) (2002), 251-338.
5. M.S. Forman, J.Q. Trojanowski and V.M.-Y. Lee, Neurodegenerative diseases: A decade of discoveries paves the way for therapeutic breakthroughs, Nat Med 10 (2004), 1055-1063.
6. M. Hong, V. Zhukareva, V. Vogelsberg-Ragaglia, Z. Wszolek, L. Reed, B.I. Miller, D.H. Geschwind, T.D. Bird, D. McKeel, A. Goate, J.C. Morris, K.C. Wilhelmsen, G.D. Schellenberg, J.Q. Trojanowski and V.M.-Y. Lee, Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17, Science 282 (1998), 1914-1917.
7. M. Hutton, C.L. Lendon, P. Rizzu, M. Baker, S. Froelich, H. Houlden, S. Pickering-Brown, S. Chakraverty, A. Isaacs, A. Grover, J. Hackett, J. Adamson, S. Lincoln, D. Dickson, P. Davies, R.C. Petersen, M. Stevens, E. de Graaff, E. Wauters, J. van Baren, M. Hillebrand, M. Joosse, J.M. Kwon, P. Nowotny, L.K. Che, J. Norton, J.C. Morris, L.A. Reed, J.Q. Trojanowski, H. Basun, L. Lannfelt, M. Neystat, S. Fahn, F. Dark, T. Tannenberg, P. Dodd, N. Hayward, J.B.J. Kwok, P.R. Schofield, A. Andreadis, J. Snowden, D. Craufurd, D. Neary, F. Owen, B.A. Oostra, J. Hardy, A. Goate, J. van Swieten, D. Mann, T. Lynch and P. Heutink, Association of missense and 5′-splice-site-mutations in tau with the inherited dementia FTDP-17, Nature 393 (1998), 702-705.
8. T. Ishihara, M. Hong, B. Zhang, Y. Nakagawa, M.K. Lee, J.Q. Trojanowski and V.M.-Y. Lee, Age-dependent emergence and progression of a tauopathy in transgenic mice engineered to overexpress the shortest human tau isoform, Neuron 24 (1999), 751-762.
9. V.M.-Y. Lee, B.J. Balin, L. Otvos Jr. and J.Q. Trojanowski, A68: A major subunit of paired helical filaments and derivatized forms of normal tau, Science 251 (1991), 675-678.
10. V.M.-Y. Lee, R. Daughenbaugh and J.Q. Trojanowski, Microtubule stabilizing drugs for the treatment of Alzheimer's disease, Neurobiol Aging 15 (1994), S87-S89.
11. V.M.-Y. Lee, M. Goedert and J.Q. Trojanowski, Neurodegenerative tauopathies, Annu Rev Neurosci 24 (2001), 1121-1159.
12. V.M.-Y. Lee, T.K. Kenyon and J.Q. Trojanowski, Transgenic animal models of tauopathies, Biochem Biophys Acta 1739 (2005), 251-259.
13. M.L. Michaelis, S. Ansar, Y. Chen, E.R. Reiff, K.I. Seyb, R.H. Himes, K.L. Audus and G.I. Georg, Beta-amyloid- induced neurodegeneration and protection by structurally diverse microtubule-stabilizing agents, J Pharmacol Exp Ther 312 (2005), 659-668.
14. P. Poorkaj, T.D. Bird, E. Wijsman, E. Nemens, R.M. Garruto, L. Anderson, A. Andreadis, W.C. Wiederholt, M. Raskind and G.D. Schellenberg, Tau is a candidate gene for chromosome 17 frontotemporal dementia, Ann Neurol 43 (1998), 815-825.
15. A. Rice, Y. Liu, M.L. Michaelis, R.H. Himes, G.I. Georg and K.L. Audus, Chemical modification of paclitaxel (Taxol) reduces P-glycoprotein interactions and increases permeation across the blood-brain barrier in vitro and in situ, J Med Chem 48 (2005), 832-838.
16. S. Roy, B. Zhang, V.M.-Y. Lee and J.Q. Trojanowski, Axonal transport defects: A common theme in neurodegenerative diseases, Acta Neuropathol 109 (2005), 5-13.
17. M.G. Spillantini, T.R. Murrell, M. Goedert, M.R. Fallow, A. Klug and B. Ghetti, Mutation in the tau gene in familial multiple system tauopathy with presenile dementia, Proc Natl Acad Sci USA 95 (1998), 7737-7741.
18. J.Q. Trojanowski, D. Huryn, A.B. Smith 3rd and V.M.-Y. Lee, Microtubule stabilizing drugs for therapy of Alzheimer's disease and other neurodegenerative disorders with axonal transport impairments, Expert Opin Pharmacother (2005), in press.
19. B. Zhang, A. Maiti, S. Shively, F. Lakhani, G. McDonald-Jones, J. Bruce, E.B. Lee, S.X. Xie, S. Joyce, C. Li, P.M. Toleikis, V.M.-Y. Lee and J.Q. Trojanowski, Microtubule binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a murine neurodegenerative tauopathy model, Proc Natl Acad Sci USA 102 (2005), 227-231.